Autonomix Medical, Inc., a development stage medical device company, focuses on advancing technologies for sensing and treating disorders relating to the peripheral ...
Autonomix Medical, Inc. (AMIX) is headquartered in The Woodlands, Texas and operates as a development-stage healthcare/medical-device company. The company’s core goal is to enable more accurate diagnosis and more effective treatment of diseases involving the peripheral nervous system by combining sensing, signal differentiation, and targeted therapy approaches. Business and technology ...Autonomix Medical, Inc. (AMIX) is headquartered in The Woodlands, Texas and operates as a development-stage healthcare/medical-device company. The company’s core goal is to enable more accurate diagnosis and more effective treatment of diseases involving the peripheral nervous system by combining sensing, signal differentiation, and targeted therapy approaches.
Business and technology focus: Autonomix’s technology platform centers on a catheter-based, microchip-enabled sensing array designed to detect and differentiate peripheral neural signals. The platform is intended to support precision nerve-targeted therapies—effectively providing a “real-time” understanding of relevant nervous-system signals so that treatment can be better targeted to the underlying disorder rather than relying solely on non-specific clinical signals.
Product and services: As a medical device developer, Autonomix’s “product” is primarily its evolving sensing/therapy platform and related device configurations, along with the associated development program needed to translate the technology into clinically usable systems. The company’s public materials indicate early focus areas such as chronic pain management and indications related to pancreatic cancer, with broader applicability to hypertension, cardiovascular, and other nerve-related disorders. In this stage of development, revenue generation is typically driven by R&D progression, partnerships, and eventual commercialization rather than by mature recurring product sales.
Cost structure and BOM considerations (high-level): Like many early medical-device organizations, major costs generally include engineering and clinical-development activities (hardware/software prototyping, microelectronics integration, reliability testing, regulatory and clinical work), plus manufacturing process development. While specific bill-of-materials (BOM) figures are not provided in the supplied data, the sensing array and catheter system imply a device BOM that may include microelectronics, packaging/encapsulation, catheter components, sensors, and quality/testing consumables—costs that often scale with design complexity and regulatory-grade manufacturing requirements.
Financial signals and outlook: The supplied fundamentals data reflect development-stage economics, including negative profitability measures (e.g., negative earnings/FCF ratios and negative return metrics). Market valuation and liquidity indicators (e.g., current market cap and trading volume) are present, but detailed segment revenue, gross margin, and operating profit margins are not meaningfully positive in the dataset—consistent with ongoing R&D rather than established commercial sales.
Key people and leadership: Leadership includes Bradley A. Hauser as CEO (with additional leadership/co-founder roles noted in the provided materials). The company also references experienced medical-device leadership, which is often critical for navigating regulatory pathways and translating engineering prototypes into clinically validated devices.
Wishes/trajectory: The company’s central “wish” is commercialization of a first-in-class platform that acts as a foundational technology for precision peripheral nerve treatment. Near-to-mid-term milestones would typically include advancing clinical evidence, progressing regulatory submissions, establishing scalable manufacturing, and building strategic partnerships to accelerate adoption in target therapeutic areas.
YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength.
QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes.
RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three).
$0
—
—
Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day.
$-16.7M
-46.5%
-2.3%
Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials.
—
—
—
Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on).
—
—
—
Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales.
—
—
—
Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock.
$-12.3M
-48.6%
-22.4%
FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine.
—
—
—
Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe.
0.0%
—
—
Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking.
4.45x
-21.0%
+9.0%
Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground.
